To analyze the cost-effectiveness of treating hypertensive patients with azilsartan medoxomil and chlorthalidone fixed dose combination (AZL-M/ CLD FDC) therapy compared with other angiotensin receptor blocker (ARB) and hydrochlorothiazide (HCT) combinations commonly available in the US market. METHODS: A Markov Cohort Simulation approach was utilized. Simulated patients start in a hypertensive state and are followed over multiple time periods as they transition between mutually exclusive health states. Cost per Quality Adjusted Life Year (Cost/QALY) and Incremental Cost-effectiveness Ratios (ICERs) are calculated over all possible dose combinations. Cardiovascular disease (CVD) risks were based on the Framingham risk equations. FDCs of HCT and eight ARBs commonly used in the US market (Atacand HCT, Avalide, Benicar HCT, Hyzaar, Diovan HCT, generic Losartan HCT, Micardis HCT and Teveten HCT) were included in the analyses. RESULTS: Results suggest that AZL-M/CLD FDC is less expensive and more effective in lowering BP versus all branded ARB/HCT FDC comparators. When considering average costs and the CVD risks based on the Framingham risk equations for all therapies over a five year time horizon, AZL-M/CLD FDC would remain the least expensive and most effective branded ARB/Diuretic FDC therapy up to a 23.5% unit cost increase with the average office SBP reduction of -22.3% and up to 18.1% unit cost increase with the 24-hour ambulatory BP reduction of -17.0%. CONCLUSIONS: AZL-M/CLD FDC is predicted to be less expensive and more effective in reducing blood pressure and cardiovascular risk when compared to all branded ARB/HCT FDC comparators during a five year time horizon.
OBJECTIVES:
To estimate the cost-effectiveness of Dabigatran compared to Warfarin in non-complicated atrial fibrillation in Colombia. METHODS: We developed a Markov model to represent the health states of atrial fibrillation and its complications;6 health states and 2 transitional states were considered,including disabling and non-disabling stroke, myocardial infarction, pulmonary embolism and death. Major and minor hemorrage were considered transitory in the model. Probabilities were derived from published clinical trials. Resource use was estimated from the Colombian Society of Cardiology guidelines and validated to adjust to usual practice. Direct medical costs were derived from different sources (public and private) and indirect costs (predicted wages lost and transportation costs) were obtained from the most recent National Health Survey. Utilities were obtained from a systematic literature review. Two separate analysis, payer and societal perspective, were performed in a 20-year horizon. Maximum and minimum values of effectiveness and resource use were included in the sensitivity analysis. The results were discounted at 3% annually. RESULTS: After 20 years of follow up, discounted direct medical costs accounted for USD$70,500 for Warfarin and $78,840 and $79,860 for 150mg and 110mg of Dabigatran, respectively. When taking into account indirect costs, Warfarin increased their costs by 13% while Dabigatran costs were increased by 9%. Estimated life years for Dabigatran were higher (9.40 and 9.29 for 150mg and 110mg, respectively) as well as the QALYs (8.48, 8.39 ) than for Warfarin 9.09 LY and 8.12 QALYs. The calculated ICER was $23,760 and $34,690 per additional QALY when taking into account direct costs and even lower when considering indirect costs. CONCLUSIONS: In Colombia, the use of Dabigatran for the management of non-complicated atrial fibrilation compared to Warfarin increases years of life and QALYs. Assuming a similar willingnes-to-pay as for other cardiovascular interventions, dabigatran is a cost-effective intervention. . Sensitivity analysis demonstrated stability of results, changing cost of hospitalization and cost of urapidil the advantage of urapidil from the position of "cost-effectiveness" was still obviously. CONCLUSIONS: Treatment of hypertension urgencies with urapidil is a dominated alternative from the perspective of the health economics. 
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PCV53 A COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND STANDARD TREATMENT FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN SLOVAKIA
OBJECTIVES:
To compare the costs and effectiveness of dabigatran etexilate with current standard treatment in patients with non-valvular atrial fibrillation (NVAF), from the Slovakian health care system perspective. METHODS: A previously published Markov cohort model was adopted to estimate the outcomes of patients with dabigatran (150mg BID, 110mg BID) in its labelled indication during their lifetime for the following health states: ischemic and haemorrhagic stroke, transient ischemic attack, systemic embolism, intracranial and extracranial haemorrhage, acute myocardial infarction, minor bleeds and death. Data on event rates and patient quality of life associated with different health states and patient survival time was based on the RE-LY trial and the literature. The base-case consisted of a cohort of patients with NVAF, CHADS 2 Ն1 and no contraindications to anticoagulation therapy. The modelled consequences of the clinical events were costs, disability and/or reduction in quality of life and death. Data on resource use associated with patient management and different events were estimated using a Slovakian expert panel, while unit prices were collected from the official sources update 2011. One-way sensitivity analyses was used on all relevant variables to test the robustness of the analysis. RESULTS: The dabigatran group had more life years and QALYs gained compared to standard treatment (warfarin, aspirin, clopidogrel and no treatment); these gains were primarily driven by a lower incidence of the intracranial events and systemic embolism. A cohort of 5,000 patients treated with dabigatran during their lifetime gained 40,238 QALYs (standard: 38,178 QALYs) with incremental costs of €35.9mill (standard: €37.3 mill). The incremental cost-effectiveness ratio (ICER) of dabigatran versus standard treatment was estimated at €17,437, below the Slovakian acceptable threshold (€18,000 per QALY gained). The sensitivity analysis consistently demonstrated the cost-effectiveness of dabigatran. CONCLUSIONS: Dabigatran represents a cost-effective treatment for preventing strokes in patients with NVAF in Slovakia.
PCV54
COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN COMPARED TO WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN A MEDICARE POPULATION
Ward MA, Biddle AK University of North Carolina, Chapel Hill, NC, USA OBJECTIVES: Dabigatran was approved in the United States to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). Dabigatran has several potential advantages over the current standard of care (warfarin), including a generally better side effect profile, fewer drug interactions, and no international normalized ratio (INR) monitoring, but it is considerably more expensive. The objective of this analysis was to determine the cost-effectiveness of dabigatran versus warfarin for AF in a Medicare population. METHODS: A Markov model was used to simulate outcomes for patients aged 65 with AF and a (CHADS 2 ) congestive heart failure, hypertension, age, diabetes, prior stroke [doubled] score Ն1. A 5-year time horizon and a managed care perspective were employed in this analysis. Data comparing the clinical performance of dabigatran and warfarin was derived from the RE-LY trial. Quality-adjusted life-years (QALYs) were used to assess outcomes and utility weights were obtained from systematic reviews. Direct medical costs associated with complications from AF were based on hospitalization costs for diagnostic-related groups and reported in U.S. 2011 dollars. RESULTS: Over a 5-year period, the incremental cost-effectiveness ratio (ICER) for dabigatran 150 mg was $26,551 per QALY compared to warfarin. The ICER was most sensitive to the utility associated with the well state for each of the alternatives as well as the price of dabigatran, warfarin, and INR monitoring needed for warfarin therapy. In probabilistic analyses, dabigatran was cost-effective in 91% of simulations at a $50,000/QALY threshold. CONCLUSIONS: Prescribing dabigatran increases qualityadjusted life expectancy for AF patients at a cost considered acceptable by American payers.
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